Merkel cell polyomavirus tumor antigen presented on MHC class I (MCPyV T antigen (MHC I))

Merkel cell polyomavirus tumor antigens presented on MHC class I comprise mainly the truncated large T (LT) and small T (sT) oncoproteins of MCPyV, which are clonally integrated and continuously expressed in most cases of Merkel cell carcinoma (MCC), a highly aggressive neuroendocrine skin cancer[2][4][6]. These viral proteins act as shared tumor neoantigens that are the primary targets of anti-tumor CD8+ T cell responses in virus-positive MCC[2][4][6]. Their recognition by T cells is strongly correlated with improved clinical outcomes, and anti-MCPyV antibody titers are used clinically for patient monitoring as biomarkers[2][4][6]. Targeting these antigens is the basis for immunotherapeutic strategies, including immune checkpoint blockade, adoptive T-cell transfer, and vaccines[4][6]. However, MCC often employs immune evasion via downregulation of MHC class I or components of its antigen processing machinery, posing challenges to therapeutic efficacy and requiring combination approaches such as HDAC inhibition to restore antigen presentation[1][3][7].\n\nKey details:\n- Therapeutic target: Yes; central in MCC immunotherapy research and clinical management[2][6].\n- Nature: These are not innate human proteins but foreign (viral) tumor-specific antigens that are unique to MCPyV-infected cancers and presented on the surface of tumor cells via MHC class I[2][4][6].\n- Drug strategies: Current drugs (mainly immune checkpoint inhibitors) rely on reactivating the immune system to recognize and kill cells presenting these antigens, while emerging strategies include engineered T cells and combination immuno/epigenetic therapies[3][4][6].\n- Disease: Almost exclusive to MCPyV-associated Merkel cell carcinoma, which accounts for approximately 80%* of MCC cases[2][4].\n- Biomarker role: Anti-MCPyV T antigen antibodies (serology) are standard-of-care for monitoring recurrence; assessment of MHC class I and antigen expression can help guide therapeutic decisions[2][4][6].\n\nIf further specificity is needed (e.g., distinguishing large T vs. small T antigen, or mapping specific epitopes), molecular and clinical sources recommend referring to published MCPyV epitope libraries, as many reagents and ongoing trials now employ individual peptides or restricted HLA-tetramers for patient-specific therapy[2][4][6].

Other names

Merkel cell polyomavirus T antigen (MCPyV T antigen)MCPyV large T antigen (LTA)MCPyV small T antigen (sT)MCPyV oncoproteinsMCPyV tumor antigen (T-Ag)

Induction of cytotoxic T cell–mediated killing (CD8+ T cells recognize MCPyV antigens presented on MHC class I); Immune checkpoint inhibition (restores T cell function against MCPyV+ tumor cells); Epigenetic reprogramming (HDAC inhibitors restore MHC I and antigen processing machinery)